PRO trial: Análise final de 2 anos mostrou ganho de SG de 8 meses com acompanhamento via web dos sintomas dos pctes com Ca pulmão comparado ao seguimento apenas com TCs 3-6m #MOCnaASCO #ASCO18 MOC Brasil Fabio Schutz Ricardo Carvalho @lvsantosmd cayamada @MelanomaSarcoma

Phase I trial of Durvalumab+ Tremelimumab demonstrated promising activity in previously treated ED-SCLC. ORR: 13.3%. mOS: 7.9m; 12mOS: 41%. However, 1 out of 4 pts experienced G3/4 toxicity. #MOCnaASCO18 #MOCBrasil #SCLC

SEER Database Analysis n= 15.644 pts - PORT in resected NSCLC... N2 w/out Chemo: ⬇️ in OS N0 and N1: ⬇️ OS Poster Abs 8522 #MOCnaASCO #MOCBrasil

[KN-158 - Phase2 Pembrolizumab single arm in r/r ED-SCLC] n=107; 40% PDL1+ ORR - PDL1 positive: 35% / PDL1 neg: 6% mOS - PDL1 pos: 14.9 m / PDL1 neg: 5.9 m Promising antitumor activity, especially in PDL1 + #MOCnaASCO #MOCBrasil

[TRINITY ph 2 ROVA-T in DLL3+ ED-SCLC with 2 or more prior regimens] n=339 - ORR: 12% / mOS: 5.6m in DLL3 high IHC (>75% cells +): n=238 - ORR: 24% / mOS:5.7m However, toxicities G>=3: 40% (pleural effusion, thrombocytopenia, fatigue) #MOCnaASCO #MOCBrasil

Publicado no Journal of Clinical Oncology Dados atualizados do KEYNOTE-001 de Sobrevida Global em 5 anos nos pctes com Ca Pulmão metastático tratados com Pembrolizumabe #LungCancer #LCSM #immunotherapy Carolina Kawamura Haddad Fernando Moura Manoel Carlos cayamada Rosely Yamamura Fabio Schutz

Não adie ou suspenda seu tratamento, pode prejudicar suas chances de CURA. Não menospreze seus sintomas, também pode prejudicar suas chances de CURA!

Single-cell seq of axicabtagene CAR T cell infusions used in pts with LBCL shows association between high CD8+ T cell freq & better responses, and CD8+ exhaustion signatures & worse resp. A monocyte-like transc sign was associated with high-grade ICANS nature.com/articles/s4159…

🚨⭐️Snapshot: Trial Types in Precision Medicine Cell OncoAlert

instagram.com/p/CULetypJ1Xe/…

Superb presentations and discussion this morning of our EGFRmut patients with our Brazilian colleagues here at the Hospital Albert Einstein Center (Sao-Paulo) Einstein Hospital Israelita. A pleasure to be present with Mihaela Aldea Thanks for the invitation! Gustave Roussy

Pancreatic cancer 5-yr survival rate nearly 30% w/ addition of capecitabine after surgery bit.ly/1O77qxV #ASCO16

#ASCO16 Biosimilar trastuzumab is comparable to the original, opens way for more affordable treatment. ASCO

So many driver mutations now identified! Now, only 30% of NSCLC pts have no mutation #ASCO16 #lcsm

Nivolumab (N) and ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC) #ASCO16 ow.ly/JTML300V5oC

#immunotherapy: The theme of #asco16 and the future of #oncology onclive.com/conference-cov…

Every cell contains genes that tell it how to behave. When those genes malfunction it can lead to cancer.